159 related articles for article (PubMed ID: 36312489)
1. Secondary light chain amyloidosis with Waldenström's macroglobulinemia and intermodal marginal zone lymphoma: A case report.
Zhao ZY; Tang N; Fu XJ; Lin LE
World J Clin Cases; 2022 Oct; 10(29):10779-10786. PubMed ID: 36312489
[TBL] [Abstract][Full Text] [Related]
2. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
[TBL] [Abstract][Full Text] [Related]
3. A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström's macroglobulinemia.
Patel D; Sidana M; Mdluli X; Patel V; Stapleton A; Dasanu CA
J Oncol Pharm Pract; 2022 Dec; 28(8):1917-1921. PubMed ID: 35306909
[TBL] [Abstract][Full Text] [Related]
4. Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).
Bou Zerdan M; Valent J; Diacovo MJ; Theil K; Chaulagain CP
Adv Hematol; 2022; 2022():1182384. PubMed ID: 35096069
[TBL] [Abstract][Full Text] [Related]
5. With M-protein positive, could transthyretin amyloidosis be easily excluded? Not necessarily! Wild-type transthyretin amyloidosis with Waldenström's macroglobulinaemia: a case report.
Kinoshita H; Sugino H; Ishikawa A; Kido M; Kanegawa M; Kashiwabara A; Sumimoto Y; Masada K; Shimonaga T; Oka T
Eur Heart J Case Rep; 2022 Nov; 6(11):ytac414. PubMed ID: 36339457
[TBL] [Abstract][Full Text] [Related]
6. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Panayiotidis P; Tumyan G; Thieblemont C; Ptushkin VV; Marin-Niebla A; García-Sanz R; Le Gouill S; Stathis A; Bottos A; Hamidi H; Katz P; Perretti T; Willis JC; Buske C
Leuk Lymphoma; 2022 May; 63(5):1058-1069. PubMed ID: 35045765
[TBL] [Abstract][Full Text] [Related]
7. An unusual case of Waldenstrom's macroglobulinemia presented with nasopharyngeal involvement.
Sathyanarayanan V; Das U; Shankaranand B; Gupta S; Anvekar NJ; Lakshmaiah K
Ecancermedicalscience; 2013; 7():362. PubMed ID: 24171046
[TBL] [Abstract][Full Text] [Related]
8. A case of systemic amyloidosis showing papular/nodular lesions due to Waldenström's macroglobulinemia.
Toma Y; Nobeyama Y; Matsuzaki H; Yasuda KI; Asahina A
Clin Case Rep; 2023 May; 11(5):e7346. PubMed ID: 37205153
[TBL] [Abstract][Full Text] [Related]
9. Amyloidosis and Waldenström's macroglobulinemia.
Gertz MA; Merlini G; Treon SP
Hematology Am Soc Hematol Educ Program; 2004; ():257-82. PubMed ID: 15561687
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
11. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
12. Relapsed Waldenstrom's Macroglobulinemia and Therapy-Related Myelodysplastic Syndrome with Complex Cytogenetics: A Treatment Dilemma.
Kalantri S; Singh I; Yang L; Abuelgasim KA
Case Rep Oncol; 2023; 16(1):351-356. PubMed ID: 37384207
[TBL] [Abstract][Full Text] [Related]
13. Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.
Amaador K; Thieblemont C; Trotman J; Minnema MC
Hematol Oncol; 2023 Jul; ():. PubMed ID: 37458281
[TBL] [Abstract][Full Text] [Related]
14. [Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].
Zhang DD; Hu PZ; Li P; Jiang GZ; Yin YH; Wang GN; Zhao WG; Zhang YP; Li WC
Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):592-597. PubMed ID: 34078045
[No Abstract] [Full Text] [Related]
15. Bilateral, persistent serous macular detachments with Waldenström's macroglobulinemia.
Pilon AF; Rhee PS; Messner LV
Optom Vis Sci; 2005 Jul; 82(7):573-8. PubMed ID: 16044069
[TBL] [Abstract][Full Text] [Related]
16. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
[TBL] [Abstract][Full Text] [Related]
18. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
19. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
[TBL] [Abstract][Full Text] [Related]
20. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
